How can I safely discontinue atomoxetine (Strattera) and start mixed‑amphetamine (Adderall) therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switching from Strattera (Atomoxetine) to Adderall (Mixed Amphetamine Salts)

Atomoxetine can be discontinued abruptly without tapering when switching to Adderall, as it does not cause rebound symptoms or discontinuation syndrome 1, 2.

Discontinuation Protocol for Atomoxetine

  • Stop atomoxetine immediately – no taper required 1
  • Atomoxetine can be discontinued without risk of symptom rebound or discontinuation-emergent adverse effects 2
  • The FDA label explicitly states "STRATTERA can be discontinued without being tapered" 1
  • Patients may miss occasional doses without rebound effects 3

What to Expect After Stopping Atomoxetine

  • ADHD symptoms will worsen after discontinuation but typically do not return to pretreatment levels 2
  • Common adverse events from atomoxetine (nausea, fatigue, decreased appetite) resolve within 3-53 days, with most resolving within the first week 4
  • Blood pressure and heart rate increases from atomoxetine return to baseline upon discontinuation 4
  • Male sexual side effects may take longer to resolve (up to 53 days median) 4

Initiating Adderall

Before starting Adderall, obtain cardiac history:

  • Personal history of cardiac symptoms, seizures, or prior EEG abnormalities 5, 6
  • Family history of sudden death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, or long QT syndrome 5
  • If risk factors present, obtain ECG and consider cardiology referral 5

Start Adderall immediately after stopping atomoxetine:

  • No washout period is required between medications
  • Begin with standard starting doses per FDA labeling 6
  • Monitor blood pressure and heart rate at each visit, as stimulants cause mild increases (1-2 bpm HR, 1-4 mmHg BP on average) 5

Key Differences to Anticipate

Onset of effect:

  • Atomoxetine requires 6-12 weeks for full therapeutic effect 7
  • Adderall has rapid onset – effects observed within hours of first dose 7

Duration of coverage:

  • Atomoxetine provides "around-the-clock" symptom control 7
  • Adderall formulations vary: immediate-release lasts 4-6 hours; extended-release formulations provide 8-12 hours of coverage
  • Patients may experience afternoon/evening rebound when Adderall wears off 7

Side effect profile:

  • Adderall causes more appetite suppression and potential growth effects compared to atomoxetine 5, 7
  • Adderall is a controlled substance with abuse potential; atomoxetine is not 7
  • Both medications can increase blood pressure and heart rate 5

Special Considerations

If patient has comorbid substance use disorder:

  • The switch from atomoxetine to stimulants should be approached cautiously, as atomoxetine is preferred first-line in active substance use disorders 7, 8
  • Long-acting stimulant formulations reduce abuse potential if stimulants are necessary 9

Monitoring during transition:

  • Assess ADHD symptoms weekly for the first month after switching
  • Monitor vital signs (BP, HR) at each visit during titration 5
  • Watch for emergence of tics, psychotic symptoms, or mood changes 5, 6
  • Monitor appetite and weight, especially in children 5

Common pitfall to avoid:

  • Do not overlap medications or cross-taper – simply stop atomoxetine and start Adderall the next day
  • While atomoxetine can be co-administered with stimulants safely during switching 3, this is unnecessary given atomoxetine's lack of discontinuation syndrome

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.